Research published by Cancer Management & Research explores the efficacy of treating multiple malignancies with immune checkpoint inhibitors and programmed cell death-1 inhibitors (PD-1). The review specifically analyzes the presence of pneumonitis as an adverse event following treatment of checkpoint inhibitors.
Research published by Cancer Management & Research explores the efficacy of treating multiple malignancies with immune checkpoint inhibitors and programmed cell death-1 inhibitors (PD-1). The review specifically analyzes the presence of pneumonitis as an adverse event following treatment of checkpoint inhibitors.
The immune checkpoint inhibitors are intended to target cytotoxic T-lymphocyte antigen 4 (CTLA-4) and PD-1, in order to block negative T-cell regulators and promote antitumor immune activity. Pneumonitis is one of the potential life-threatening immune-relate adverse events (irAEs) that are associated with checkpoint inhibition.
When reviewing the epidemiology of checkpoint inhibitor-related pneumonitis (CIP), the researchers discussed the rare occurrences of CIP. In a clinical trial, there was a less than 5% occurrence in patients treated with a monotherapy and a slightly greater than 5% incidence of those treated with a combination therapy.
Pneumonitis is less common among patients with anti-CTLA-4 treatment than those with anti-PD-1 treatment, according to the review. The risk of the adverse effect disease also may be influenced by the tumor type and greater in patients with non-small cell lung cancer. However, there are no specific or direct patient risk factors that can be determined for those that develop the pneumonitis.
An early diagnosis of CIP contributes to the efficacy of the necessary treatment. Grade 2 pneumonitis can often be treated with steroids, as they do not affect the efficacy of the immunotherapy. Grade 3/4 pneumonitis patients however, should be admitted to a hospital due to the severity of their symptoms and the life-threatening risks. The review also suggests that not who experience moderate to severe pneumonitis stop receiving their checkpoint inhibitor doses.
“The introduction of the immune checkpoint inhibitors has reinvigorated the management of a number of malignancies. Anti-CTLA-4 and anti-PD-1 agents have demonstrated marked efficacy in the treatment of advanced cancers and have shed light on new tumor biologic and immunologic principles,” concluded the review. “Nonetheless, immunotherapy is associated with rare but potentially life-threatening irAEs. The widespread use of these agents demands a greater understanding of the clinical manifestations, diagnosis, and treatment of these side effects.”
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More